Skip to main content

Table 1 Demographic, clinical and surgical characteristics for the overall population

From: Guideline compliance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and factors associated with non-compliance

  Patients
N = 256
Demographic characteristics
 Male sex 143 (55.9)
 Age (years), mean (SD) 74.76 (10.59)
Clinical characteristics
 AT9 Thromboembolic risk
  Low 135 (52.7)
  Moderate 38 (14.8)
  High 40 (15.6)
  Other VKA indication a 33 (12.9)
  Risk factors unknown 10 (3.9)
 Atrial fibrillation 190 (74.2)
 Mechanical heart valve 20 (7.8)
 Venous thromboembolism 34 (13.3)
 Previous thromboembolic event during VKA interruption 3 (1.2)
 iCVA/TIA 37 (14.5)
 Thrombophilia 7 (2.7)
 Coronary heart disease 74 (28.9)
 Heart failure 20 (7.8)
 Hypertension 129 (50.4)
 Diabetes mellitus 62 (24.2)
 Active cancer/malignancy 54 (21.5)
 Previous bleedingb 13 (5.1)
 VKA regimen
  Acenocoumarol 203 (79.3)
  Phenprocoumon 53 (20.7)
 Length of stay (days): median (IQR) 6 (3–10)
Surgery characteristics
 Elective 181 (70.7)
 Type of 1st surgery
  Urologic 40 (15.6)
  Orthopaedic 89 (34.8)
  Gastrointestinal 52 (20.3)
  Vascular 36 (14.1)
  Other 39 (15.2)
 Surgical bleeding risk
  High 209 (81.6)
  Moderate 44 (17.2)
  Low 3 (1.2)
  1. Results are expressed as n (%) unless stated otherwise
  2. AT9 Antithrombotic Therapy and Prevention of Thrombosis, Ninth Edition guideline, iCVA ischaemic cerebrovascular accident, IQR inter quartile range, SD standard deviation, TIA transient ischaemic attack, VKA vitamin-K antagonist
  3. a No AT9 risk classification is available for VKA indications other than atrial fibrillation, mechanical heart valves and venous thromboembolism
  4. b Any previous bleeding event annotated in the medical record